Tiyonnoh Cash

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement

Namita Goyal, Tiyonnoh Cash, Uazman Alam et al. · Journal of Neurology Neurosurgery & Psychiatry · 2015 · 97 citations · Full text

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial

Christopher Grunseich, Ram R. Miller, Therese Swan et al. · The Lancet Neurology · 2018 · 40 citations

Clinical Trials, Preliminary Efficacy, Bulbar Muscular Atrophy +4

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa et al. · Therapeutic Advances in Neurological Disorders · 2020 · 26 citations · Full text